AbbVie’s Rinvoq Lands FDA Approval as First Oral Drug for Crohn’s Disease
FDA approval of blockbuster AbbVie drug Rinvoq makes it the first oral therapy for moderately to severely active Crohn's disease. The regulatory nod is the seventh for the drug, which belongs to a class of therapies called JAK inhibitors.
